Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jae Keith Joung
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Beam Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Beam Therapeutics is developing therapeutics based on base editing technology, a specific type of genome editing technology. This research grant is focused on characterizing genome editing parameters in T cells, and developing genome editing techniques to improve the safety, efficacy, and manufacturing of engineered T cells for adoptive cell therapy. The results of this research could be of interest to the company. Therefore, the institution determined that, based on the close connection between the interests of the company and this research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Optimizing Cancer Immunotherapy Safety and Efficacy using Genome Editing
PROJECT NARRATIVE In the field of cancer immunotherapy, patient derived T cells are engineered to recognize and kill tumor cells that express cancer- or lineage-specific antigens. Genome editing strategies have been proposed to improve the efficacy of this approach, yet the safety and efficiency of gene editing in patient derived T cells has not been assessed. This proposal will thoroughly characterize important genome editing parameters in T cells, and will develop and implement genome editing techniques to improve the safety, efficacy, and manufacturing of engineered T cells for adoptive cell therapy.
Filed on August 01, 2017.
Tell us what you know about Jae Keith Joung's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jae Keith Joung”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Editas Medicine | >$600,000 |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Pairwise Plants | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Editas Medicine | $10,000 - $19,999 |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Transposagen Biopharmaceuticals | Value cannot be readily determined |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Hera Testing Laboratories | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Beacon Genomics | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Poseida Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.